1. CURRICULUM VITAE
RICHARD L. WURDEMAN
PERSONAL INFORMATION
Home: 17086 S. Reflection Circle
Bennington, Nebraska 68007
Marital Status: Married (Jolene); three children
Pharmacy Licensure: Iowa, Nebraska
CAREER SUMMARY
Senior Scientific Liaison; Janss en Scientific Affairs, AstraZen e c a
Scientific Affairs.
• Actively engaged and developed strategic relationships with key
opinion leaders across a broad spectrum of cardiovascular
diseases and therapies, i.e. anticoagulation, antiplatelet,
hypertension, heart failure, hyperlipidemia, diabetes, and
metabolic syndrome. The strategy to engage thought leaders
was consistent with the goals and objectives for each respective
cardiovascular drug portfolio. The active target list consisted of
approximately 60- 80 key opinion leaders. This list was
comprised of both regional and national opinion leaders.
• Actively identified clinical research sites and participated in the
development and manage m e nt of company and investigator
sponsored clinical trials. This included presenting concept
proposals, assisting in protocol development, and providing
study support and education during routine visits.
• Routinely presented clinical information to healthcare
professionals and organizations. This involved numerous
presentations and in-services, both promotional, non-
promotional, and CE accredited to various health care groups,
i.e. physicians, pharmacists, nurses, formulary committees, and
multiple managed care plans. In addition facilitated various
speaker programs, ad- boards, etc.
• Routinely provided timely information to internal stakeholders
on emerging trends, and opportunities in the cardiovascular
area. “Voice of Customer Insight/competitive intelligence”

2. would approximate 100- 150 entries/year dependent on MA
objectives.
• Routinely collaborated with the commercial team providing
educational support and training in in areas of need.
• As part of training team, provided educational material, support,
and training for new- hire liaisons.
• As a member of a selected metabolic training team, provided
launch support for new DPP-4 inhibitor (saxagliptin), and
assisted in PPAR agonists training. Numerous “Above and
Beyond” awards received for various training activities.
• Worked collaboratively with numerous cross functional
teams/personal, i.e. Liaisons in other TA’s, Account Directors,
Regulatory personal, Managed Markets, and Gov’t Affairs.
• Provided scientific coverage for local, national, and international
symposiums.
Chief Clinical Research Cardiovas c ular Pharmacist/ Creighton
University Division of Cardiology; Associat e Adjunct Profes s or /
Creighton University School of Pharmacy.
• Responsible for designing and writing research protocols, IRB
submissions and presentations, coordinated multi- centered
clinical studies, evaluated data, wrote reports, and authored or
co-authored journal manuscripts for publication. Peer- reviewed
articles are listed.
• Directed/assisted fellows in research, concept proposals, IRB
submission, and abstract/manuscript submission.
• Provided numerous in-services, conducted routine grand rounds,
both pharmacy and medical, occasional didactic teaching for
pharmacy students, residents, and medical residents/fellows,
Provided ACLS pharmacology lectures.
• Director of the Cardiovascular Pharmacy Fellowship Program.
Provided student guidance in protocol development, data
collection, and manuscript submission. Provided clinical
support for both in-patient and out- patient clinics (CV).
• Lecture bureaus: Pfizer, Lilly, Schering- Plough, Novartis.
Biochemis t, Eppley Cancer Institute, University of Nebraska Medical
Center.
• Responsible for designing and writing research protocols,
Conducting chemical experiments, assays. Evaluated and
collated results. Spectrophotometers, MS, HPLC,
electrophoresis, DNA sequencing, centrifuges, radio- isotopes.
Assistan t General Manag er, B & W Manufacturing Inc.
2

3. • Manufactured farm equipment and supplies. The products were
marketed through farm chain stores in the US and Canada. Duties
included all aspects of business manage me nt, i.e. employee
supervision (15- 20), marketing, personnel, budgeting, and
inventory control.
Research Technician, University of Nebraska Medical Center.
• Research Technician in Biochemistry laboratory, small animal
experiments, all aspects of basic chemistry. Duties included
designing, conducting experiments, data analysis, writing reports,
and presenting data in journal publishable form.
EDUCATION
CREIGHTON UNIVERSITY SCHOOL OF MEDICINE, DEPARTMENT OF
CARDIOLOGY, Omaha, Nebraska 1996. Cardiology Fellowship.
UNIVERSITY OF NEBRASKA MEDICAL CENTER, COLLEGE OF PHARMACY,
Omaha, Nebraska (1990- 1994), Doctor of Pharmacy May 1994. Member Rho
Chi Honors Society. Graduated with high distinction.
UNIVERSITY OF NEBRASKA MEDICAL CENTER, Omaha, Nebraska (1975-
1978), M.S. Degree in Biochemistry. 1978
UNIVERSITY OF NEBRASKA AT OMAHA, Omaha, Nebraska (1972- 1974) B.A.
Degree in Biology, 1974
PROFESSIONAL EXPERIENCE
2013 to present: Senior Scientific Liaison, Janssen Scientific Affairs
2002 to June 2012: Senior Regional Scientific Manager, AstraZeneca LP
Pharmaceutical Company.
1996 to 2002: Associate Professor (Adjunct), Creighton University School of
Pharmacy
1996 to 2002 : Chief Clinical Research Pharmacist, Creighton Cardiac Center,
Creighton, University, Omaha, Nebraska.
1996 to 2002 : Director of PharmD. Cardiovascular Fellowship Program,
Creighton Cardiac Center, Creighton University, Omaha, Nebraska.
3

4. 1994- 1995 : Clinical/Staff Pharmacist, Dodge Country Memorial Hospital,
Fremont, Nebraska.
2012- 2013 : Community Pharmacist (part- time), McKinney’s Pharmacy,
Gretna, Nebraska
1995- 2006 : Community Pharmacist (part- time), Meodowlane Pharmacy,
Lincoln, Nebraska.
2008- 2011: Community Pharmacist (part- time), Wagge Drug, Lincoln,
Nebraska.
1987- 1993 : Research Biochemist, Eppley Cancer Institute, University
Nebraska Medical Center, Omaha, Nebraska.
1978- 1987 : Assistant Manager, B&W Mfg., Columbus, Nebraska.
1974- 1978 : Research Biochemist, University Nebraska Medical Center,
Department of Biochemistry, Omaha, Nebraska
HONORS AND SCHOLARSHIPS
REGENTS SCHOLARSHIP, UNMC
PLOUGH SCHOLARSHIP, UNMC (2 YEARS)
RHO CHI HONORS SOCIETY
EXCELLENCE IN RESEARCH AWARD 2001
PROFESSIONAL ORGANIZATIONS AND AFFILIATIONS
AMERICAN SOCIETY OF HOSPITAL PHARMACISTS
NEBRASKA PHARMACISTS ASSOCIATION
AMERICAN COLLEGE OF CLINICAL PHARMACY
AMERICAN SOCIETY OF HYPERTENSION
GRAND ROUNDS FACULTY MEMBER, EXCERPTA MEDICA, INC
SCHERING-PLOUGH SPEAKERS BUREAU
NOVARTIS SPEAKERS BUREAU
STAFF PRIVILEGES: SAINT JOSEPH HOSPITAL
PROFESSIONAL SERVICE
Pharmacy Preceptor, (1996- 2002)
BCLS/ACLS Instructor, St. Joseph Hospital, Omaha, Nebraska (1997- present).
Reviewer, Pharmacotherapy (1998- present).
4

5. Reviewer, Annals of Pharmacotherapy (2000- present).
PRESENTATIONS
22nd Annual Midwest Residents Conference, Omaha, Nebraska.
"Equivalency of fixed doses of Adalat CCR with Procardia XLR in Patients
with Essential Hypertension." April 18- 20,1996.
Smoking Cessation Educational Program; “Physiologic Effects of Smoking”,
and “Pharmacological Management of Smoking Cessation”, Creighton
University School of Medicine Continuing Medical Education Division and
Saint Joseph Physician Hospital Organization. May 21, 1999. (CE Program).
“New Strategies For AMI/ACS Management: Customized Therapies For
Optimal Survival” Continuing Education Program sponsored by Centocor,
Inc. in conjunction with Creighton University Cardiac Center. Harvey’s
Casino, Council Bluff, Iowa, August 26, 1999. (CE Program).
Optimizing ACS Patient Outcomes with IIB/IIIA Therapy. Merrillville, IN.
December 2, 1999 (Eli Lilly Lecture Bureau).
Errors in Health Care: A Leading Cause of Death and Injury. Creighton
Cardiac Center, January 26, 2000. (CE Program)
IIB/IIIA Therapy in ACS. Embassy Suites, Omaha, Nebraska, May 18, 2000
(CE Program).
New strategies in Congestive Heart Failure Treatment. Nebraska
Pharmacist’s Association Annual Meeting, Kearney, Nebraska, June 4, 2000.
(CE Program).
IIB/IIIA Therapy in Acute Coronary Syndrome. From Clinical Trials to Clinical
Practice. Creighton Cardiac Center, Omaha, Nebraska, September 28, 2000.
(CE Program).
Risk Stratification in Acute Coronary Syndrome. Omaha, Nebraska,
December 2, 2000 (Schering- Plough).
Vasculoprotective effects of ACE Inhibition, Pfizer Lecture Bureau”, 2001
The Continuum of Care: Angiotensin Receptor Blockers, Novartis Lecture
Bureau, 2001
Pharmacological Changes in the New ACLS Guidelines (CE Program) October,
2001.
5

6. Hypertension in Special Populations (CE Program) August, 2002
Managing Dyslipidemia in the New Millenium. Pharmacy CE Programs,
ACPE/Nebraska Pharmacist Assn.
June 17: Southwest Iowa Pharmacist’s Assn, Harrah’s Casino, Council
Bluffs, Iowa
June 23: Chicago Illinois, Maggiano’s Restaurant
June 24: Valparaiso, Indiana
The Challenges of Adherence. Nursing CE Program, Council Bluffs, Iowa,
May 22, 2007 (Sigma Theta Teu Int’l Omicon Epsilon Nurse Organization)
Numerous in-services, conferences, and Grand Rounds to staff cardiologists,
pharmacists, and nurses including lectures for Advanced Cardiovascular Life
Support and the School of Pharmacy, Creighton University.
ABSTRACTS AND NON- REFEREED PUBLICATIONS
Wurdeman Rl, Mohiuddin SM, Shinn BW, Hilleman DE. Cost- effectiveness of
therapeutic interchange from calcium channel blockers to fixed- dose
combination therapy in hypertension. Pharmacotherapy 1996;16:494
(Abstract).
Wurdeman RL, Mohiuddin SM, Hilleman DE. Costs and outcomes of patients
with congestive heart failure: impact of disease severity and manage me nt
approaches. Pharmacotherapy 1996;16:508 (Abstract).
Lucas BD, Hilleman DE, Mohiuddin SM, Wurdeman RL. Therapeutic
equivalence of extended- release calcium channel blockers. AJH 1996;9:168
(Abstract).
Hilleman DE, Wadibia EC, Lucas BD, Wurdeman RL. Therapeutic interchange
from calcium channel blockers monotherapy to fixed- dose combination
therapy in hypertension. AJH 1997;10 (4):107(Abstract).
Mohiuddin SM, Wurdeman RL, Hilleman DE, Lucas BD, Ryschon K. A
comparison of 24 hour blood pressure in hypertensive patients switched
from nifedipine- GITS to nifedipine- CC. AJH 1997;10(4):114(Abstract).
Hilleman DE, Ryschon KL, Mohiuddin SM, Wurdeman RL. Fixed- dose
combination versus monotherapy in hypertension: meta- analysis evaluation.
AJH 1998;11(4- II):118 (Abstract).
Seyedroudbari A, Tejani A, Hilleman DE, Wurdeman RL, Mooss AN. Cost-
minimization analysis of direct injection and infusion thrombolytic therapy in
6

7. acute myocardial infarction: a multicenter study. Pharmacotherapy
1998;18:447(Abstract).
Hilleman DE, Seyedroudbari A, Tejani A, Wurdeman RL. Cost- minimization
analysis of direct injection and infusion thrombolytic therapy in acute
myocardial infarction: a multicenter study. Circulation 1998; 98:1-
381(Abstract).
Hilleman DE, Lenz TL, Wurdeman RL. Rate control in post- CABG atrial
fibrillation: a comparison of beta- blocker versus calcium channel antagonist
with and without digoxin. Pharmacotherapy 1999;19:1195 (Abstract).
Mooss AN, Mohiuddin SM, Wurdeman Rl, Seyedroudbari SA, Hilleman DE.
Cost efficacy of esmolol versus diltiazem for atrial fibrillation/flutter
following heart surgery. Pharmacotherapy 1999;19:1195 (Abstract).
Baddigam HK, Nadri NN, Mooss AN, Amin B, Baddigam S, Amin RN, Hee TT,
Hilleman DE, Nair CK, Wurdeman RL, Ryschon K, Mohiuddin SM. Safety of
amiodarone therapy in patients with chronic obstructive pulmonary disease.
Chest 1999;116:286S(Abstract).
Mooss AN, Mohiuddin SM, Sugimoto JT, Scott W, Reyes AP, Seyedroudbari
SA, Hilleman DE, Wurdeman RL. Efficacy of esmolol versus diltiazem for
atrial fibrillation/flutter following heart surgery. Chest
1999;116:380S(Abstract).
Lenz TL, Reyes AP, Wurdeman RL, Lucas BD, Hilleman DE. Therapeutic
interchange from high- dose calcium blocker to a fixed- dose combination
product in hypertension. Pharmacotherapy 2000;20:355 (Abstract).
Lenz TL, Wurdeman RL, Reyes AP, Hilleman DE. Therapeutic interchange
among dihydropyridine calcium channel blockers: economic and formulary
considerations. Pharmacotherapy 2000;20:355 (Abstract).
Hilleman DE, Wurdeman RL, Lenz TL. Rate control in post- CABG atrial
fibrillation: A comparison of beta- blocker versus calcium antagonist with and
without digoxin. Chest 2000;116:282S(Abstract).
Wurdeman RL, Mooss AN, Lenz TL, Hilleman DE, Ryschon K. Comparative
antiarrhythmic effects of prophylactic amiodarone versus sotalol by meta-
anaysis following cardiac surgery. Chest 2000;118:109S (Abstract).
Hilleman DE, Wurdeman RL, Lenz RL, Cost- effectiveness evaluation of fixed
dose combination of angiotensin- II receptor blockers with and without
hydrochlorothiazide. AJH 2001;14(4- II): 112 (Abstract).
Li H, Riedel R, Oldemeyer B, Wurdeman R, Rovang K, Hee T. Prevention of
7

8. atrial fibrillation using antiarrhythmic drugs post cardioversion of new onset
atrial fibrillation. JACC 2002; (in press) (Abstract).
CLINICAL COORDINATOR /PRINCIPLE AND SUBINVESTIGATOR
(INDUSTRY SPONSORED MULTI-CENTERED TRIALS)
ESSENCE STUDY, GUARDIAN STUDY, EPILOG, EPISTENT, PURSUIT, PARAGON
B, OPUS, GUSTO IIB, GUSTO III, GUSTO IV AMI, ASSENT II & III, ALLHAT,
ROSETTA, COMMA, CAPRICORN, COPERNICUS, PRAISE 1 & PRAISE II, OPC-
41061, CAMELOT, EPHESUS, VALIANT, PROVE-IT, MOXCON, REPLACE, MAGIC,
PEACE, ICE.
PUBLICATIONS
Role of glucocorticoid in the enzyme overshoot response to Starvation-
refeeding [proceedings]. Berdanier, Wurdeman, Tobin. Proc- Nutr.- Soc. ,
1976, Dec, 35(3): 138A.
Further studies on the role of adrenal hormones in responses of rats to
meal- feeding. Berdanier, Wurdeman, and Tobin, Journal of Nutrition, 1976,
Vol. 106, 1791.
Studies on metabolism of glycerol by hyperlipemic & normolipemic rats.
Berdanier, Tobin, Devore, and Wurdeman. Proc. Soc. Exp. Biological
Medicine, 1978, Vol. 157, 5-11.
Enzyme overshoot in starved- refed rats: Role of the adrenal glucocorticoid.
Wurdeman, Berdanier, and Tobin. Journal of Nutrition, 1978, Vol. 108, 1457.
The effect of DNA sequence, ionic strength, and cationic DNA affinity binders
on the methylation of DNA by N-methyl- N-Nitrosourea. Wurdeman, Gold.
Chemical Research in Toxicology, 1988, 1, 146.
Synthesis of an N-methyl- N-nitrosourea linked to a methidium chloride
analogue and its reactions with 32- P-End Labeled DNA. Konakahara,
Wurdeman, and Gold. Biochemistry, 1988, 27, 8606- 8613.
N-(2-chloroethyl)- N-nitrosoureas covalently bound to nonionic and
monocationic lexitropsin dipeptides. Synthesis, DNA affinity binding
characteristics, and reactions with 32P- end- labeled DNA.Church, Wurdeman,
Zhang, Chen, Gold. Biochemistry, 1990, July 24, 29(29), 6827- 38.
Control over the sequence specificity of DNA alkylation: syntheses and
reactions with 32P- end- labeled DNA of N-alkyl-N-nitrosoureas linked to minor
groove binding lexitropsins. Gold, Church, Wurdeman, Zhang, Chen. Iarc- Sci-
8

9. Publ. 1991 (105), 439- 42.
DNA methylation by N-methyl- N-nitrosurea: methylation pattern changes in
single- and double- stranded DNA, and in DNA with mismatched or bulged
quanines. Wurdeman, Douskey, Gold. Nucleic Acids Research, 1993, Vol. 21
(21), 4975- 4980.
Sequence- specific methylation of single- and double- stranded DNA by
methylnitrosourea. Wurdeman, R. W. and Gold, B., Nitrosamines and related
N-nitroso compounds. Chemistry and Biochemistry , Eds. R. N. Loeppky and
C. J. Michejda, American Chemical Society Symposium Series 553,
Washington, D. C. (1994) pp 346- 350.
Outcomes and Cost Savings of an ACE Inhibitor Therapeutic Interchange.
Hilleman DE, Mohiuddin SM, Wurdeman RL, Wadibia EC. J Managed Care
Pharm 1997;3:219- 23.
Restenosis, the Achilles’ Heel of Coronary Angioplasty. Wurdeman RL,
Hilleman DE, Mooss A. Pharmacotherapy 1998;18(5):1024- 1040.
Comparison of Two Formulations of Nifedipine During 24- Hour Ambulatory
Blood Pressure Monitoring, A Comment. Lucas BD, Hilleman DE, Wurdeman
RL. Pharmacotherapy 1997;17(4):853- 854.
Comparison of 24 Hour Blood Pressure Data in Hypertensive Patients
Switched from Nifedipine- GITS to Nifedipine- CC. Wurdeman RL, Mooss AN,
Mohiuddin Pharmacotherapy 1999;19(1):94- 100.
Quantitative and Qualitiative Analysis of DNA Methylation at N3-Adenine by
N-Methyl- N-nitrosourea. Kelly JD, Shah D, Chen FX, Wurdeman R, Gold B.
Chem Res Toxicol 1998;11:1481- 1486.
Fixed- dose combination vs monotherapy in hypertension: a meta- analysis
evaluation. Hilleman DE, Ryschon KL, Mohiuddin SM, Wurdeman RL. Journal
of Human Hypertension 1999:13;477- 483.
Time to treatment and cost of thrombolysis: A multicenter comparison of
tPA and rPA. Seyedroudbari A, Kessler ER, Mooss AN, Wurdeman RL, Bala M,
Hilleman RL. Journal of Thrombosis and Thrombolysis 2000;9:303- 308.
Esmolol versus diltiazem in the treatment of post- operative atrial fibrillation/
atrial flutter following open heart surgery. Mooss AN, Wurdeman RL,
Mohiuddin SM, Reyes AP, Sugimoto JT, Scott W, Hilleman DE, Seyedroudbari
A. Am Heart J 2000;140:176- 80.
Benzocaine induced methemoglobinemia during an outpatient procedure.
Wurdeman RL, Mohiuddin SM, Holmberg MJ, Shalaby A. Pharmacotherapy
9

10. 2000;20(6):735- 738.
Comparative cost- effectiveness of fluvastatin and lovastatin in patients with
hypercholesteroloemia. Hilleman DE, Woodruff MP, Holmberg MJ, Wurdeman
RL, Ryschon KL, Seyedroudbari A. J Man. Care Pharm 2000:6 (3); 241- 246.
Therapeutic change of HMG-CoA Reductase inhibitors in patients with
coronary artery disease. Hilleman DE, Wurdeman RL, Lenz TL.
Pharmacotherapy 2001;21(4):410- 415.
Efficacy and safety of a therapeutic interchange from high- dose calcium
channel blockers to a fixed- dose combination of amlodipine/benazepril in
patients with moderate- to- severe hypertension. Hilleman DE, Reyes AP,
Wurdeman RL, Faulkner M. Journal of Human Hypertension 2001;15:559-
565.
Comparison of 24- hour blood pressure profiles in patients with hypertension
who were switched from amlodipine to nisoldipine. Lenz TL, Wurdeman RL,
Hilleman DE. Pharmacotherapy 2001;21 (8):898- 903.
ACE inhibitor induced bronchial reactivity in patients with respiratory
dysfunction. Packard KA, Wurdeman RL, Arouni AJ. Annals of
Pharmacotherapy 2002;36(6):1058- 67.
Amiodarone vs sotalol as prophylaxis against atrial fibrillation/flutter after
heart surgery: A meta- analysis. Wurdeman RL, Mooss AN, Mohiuddin S, Lenz
TL. Chest 2002;121:1203- 1210
Constipation, polyuria, polydipsia, and edema associated with orlistat.
Packard KA, Wurdeman RL, Reyes AP. Annals of Pharmacotherapy 2002;
36(7- 8):1168- 70
Comparison of gemfibrozil and fenofibrate in patients with dyslipidemic
coronary heart disease. Packard KA, Backes JM, Lenz TL, Wurdeman RL,
Destache C, Hilleman DE. Pharmacotherapy 2002; 22(12): 1527- 32.
Acetylcysteine in the prevention of contrast- induced nephropathy after
coronary angiography. Oldemeyer JB, Biddle WP, Wurdeman RL, Mooss AN,
Cichowski E, Hilleman DE. AHJ 2003;146(6): E23
Amiodarone versus sotalol for the treatment of atrial fibrillation after open
heart surgery: The reduction in postoperative cardiovascular arrhythmic
events (REDUCE) trial. Mooss AN, Wurdeman RL, Mohiuddin SM, Sugimoto J,
et.al. AHJ 2004; 148(4):641- 8.
10